Retatrutide met Phase 3 endpoints in TRIUMPH-1 and TRANSCEND-T2D-1
- TRIUMPH-1 met primary endpoints at 80 weeks; participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%), with 65.3% achieving BMI below 30.- In TRIUMPH-1, retatrutide reduced knee osteoarthritis pain by up to 4.3 points and obstructive sleep apnea severity by up to 36.1 events per hour.
- TRANSCEND-T2D-1 met the primary and all key secondary endpoints at 40 weeks; retatrutide reduced A1C by up to 2.0% and weight by up to 36.6 lbs (16.8%), with up to 46% achieving A1C below 5.7%.